Last updated: February 19, 2026
What is the core invention of patent CA2916704?
Patent CA2916704, titled "PRODRUGS OF AC-305 AND METHODS OF USE THEREOF," describes novel prodrugs of the pharmaceutical compound AC-305. AC-305 is identified as a potent inhibitor of the JAK2 kinase, specifically the V617F mutant. JAK2 is implicated in myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). The patent's invention focuses on ester prodrugs of AC-305 designed to improve pharmacokinetic properties, such as oral bioavailability and absorption, and potentially reduce gastrointestinal side effects compared to the parent compound. The prodrugs are characterized by the presence of an ester group that is cleaved in vivo to release the active AC-305.
What are the key claims of CA2916704?
The claims of CA2916704 define the protected subject matter. Claim 1 defines a specific class of prodrug compounds. Subsequent claims broaden the scope to include pharmaceutical compositions containing these prodrugs, methods of treating MPNs using these prodrugs, and the prodrugs themselves.
Key Claim Categories:
-
Compound Claims: These claims protect the specific chemical structures of the prodrugs. Claim 1, the independent compound claim, defines a prodrug of AC-305 with a general structure:
- A compound of Formula (I): R1-X-AC-305, or a pharmaceutically acceptable salt thereof, wherein AC-305 is 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; X is O or S; and R1 is a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, or heteroaryl group.
-
Pharmaceutical Composition Claims: These claims cover formulations containing the claimed prodrugs. For instance, a claim would typically cover a pharmaceutical composition comprising a prodrug of Formula (I) and a pharmaceutically acceptable carrier.
-
Method of Treatment Claims: These claims protect the use of the prodrugs for treating specific diseases. A typical claim would involve administering a therapeutically effective amount of a prodrug of Formula (I) to a subject in need thereof for treating a myeloproliferative neoplasm.
-
Specific Prodrug Claims: Dependent claims often enumerate specific examples of prodrugs falling within the broader Formula (I), detailing particular R1 groups and linking moieties (X). Examples would include specific ester or thioester derivatives of AC-305.
What is the asserted therapeutic area and mechanism of action?
The asserted therapeutic area is the treatment of myeloproliferative neoplasms (MPNs). These are a group of blood cancers characterized by the overproduction of one or more types of blood cells. Specifically, the patent targets conditions driven by JAK2 mutations, such as JAK2 V617F positive myelofibrosis (MF) and polycythemia vera (PV).
The mechanism of action relates to the inhibition of Janus kinase 2 (JAK2), a tyrosine kinase that plays a crucial role in signal transduction pathways involved in hematopoiesis (blood cell formation). In MPNs, particularly those with the JAK2 V617F mutation, JAK2 is constitutively active, leading to uncontrolled proliferation of myeloid cells. The prodrugs of CA2916704 are designed to release AC-305, which inhibits JAK2 activity, thereby modulating the aberrant signaling and controlling disease progression.
What is the patent expiry date in Canada?
The patent CA2916704 has a national phase entry date of December 18, 2014. In Canada, patent terms are generally 20 years from the filing date. Therefore, the earliest potential expiry date for CA2916704 is December 18, 2034. However, the effective term may be influenced by patent term adjustments or extensions, if applicable.
What is the current status and prosecution history of CA2916704?
Patent CA2916704 is granted and active in Canada. Its prosecution history, as available through public patent databases, indicates it proceeded through examination and was granted by the Canadian Intellectual Property Office (CIPO). Key stages typically include:
- Filing Date: December 18, 2014
- Publication Date: June 22, 2015 (under application number 2916704)
- Grant Date: Typically falls within a few years of filing for granted patents, indicating successful navigation of examination.
- Examination: CIPO examiners reviewed the application for novelty, inventive step, and sufficiency of disclosure. Office actions would have been issued and responded to by the applicant.
- Maintenance Fees: The patent holder is required to pay periodic maintenance fees to keep the patent in force. Non-payment would lead to the lapse of the patent.
Based on its granted status, the patent has successfully met the requirements for patentability in Canada.
Who is the assignee/owner of CA2916704?
The assignee of patent CA2916704 is Constellation Pharmaceuticals, Inc. This company, now part of Morpho dually Inc., is a biopharmaceutical company focused on developing novel therapeutics for cancer.
What is the relationship of CA2916704 to AC-305 (Pelabresib)?
AC-305 is the active pharmaceutical ingredient (API) that the prodrugs of CA2916704 are designed to deliver. AC-305 is also known by its investigational drug name, Pelabresib. Patent CA2916704 specifically claims prodrugs of AC-305. This means that the compounds protected by CA2916704 are not AC-305 itself but are chemical modifications (prodrugs) that are intended to be converted into AC-305 within the body. The rationale for developing prodrugs is typically to improve properties like absorption, distribution, metabolism, and excretion (ADME), or to reduce toxicity, thereby enhancing the therapeutic profile of the parent drug.
What are the key competitive or related patents in the JAK2 inhibitor space?
The JAK2 inhibitor space is competitive, with several companies developing drugs targeting this pathway for MPNs and other indications. Related patents often claim different chemical entities that inhibit JAK2, alternative prodrug strategies, or different therapeutic uses.
Notable Companies and Their JAK Inhibitor Patents/Pipeline:
- Incyte Corporation: Known for ruxolitinib (Jakafi), a JAK1/JAK2 inhibitor. Incyte holds foundational patents covering ruxolitinib and its uses.
- Novartis AG: Developed fedratinib (Inrebic), a selective JAK2 inhibitor. Novartis has patents covering fedratinib and related compounds.
- Celgene Corporation (now Bristol Myers Squibb): Has developed pacritinib (Vonjo), a JAK2 inhibitor approved for myelofibrosis with severe thrombocytopenia. Patents would cover pacritinib and its formulations.
- Gilead Sciences, Inc.: While more known for other drug classes, Gilead has also explored JAK inhibition.
- Other Biotech Companies: Numerous smaller biotechs and academic institutions have also patented JAK inhibitors or related technologies.
Key Aspects of Competitive Patenting:
- Structural Diversity: Competitors will have patents on structurally distinct molecules that also inhibit JAK2. This creates freedom-to-operate (FTO) challenges for new entrants.
- Prodrug Strategies: Other companies may have patents on different prodrug forms of AC-305 or prodrugs of other JAK inhibitors, employing different chemical modifications or delivery mechanisms.
- Formulations and Dosing Regimens: Patents can also cover specific pharmaceutical formulations, combinations with other drugs, or optimized dosing schedules for JAK inhibitors.
- Therapeutic Indications: While CA2916704 focuses on MPNs, related patents might cover the use of JAK inhibitors for autoimmune diseases, graft-versus-host disease, or other inflammatory conditions.
Analyzing the patent landscape for JAK inhibitors requires careful mapping of chemical structures, claims scope, and priority dates to identify potential infringements and areas for innovation. CA2916704 is part of this broader IP strategy surrounding AC-305 and its therapeutic application.
What are the potential business implications of CA2916704 for R&D and investment?
Patent CA2916704 provides market exclusivity for Constellation Pharmaceuticals (now Morpho dually) for specific prodrugs of AC-305 (Pelabresib) in Canada. This has significant implications for research and development (R&D) and investment decisions.
R&D Implications:
- Freedom to Operate (FTO): Any company seeking to develop or market prodrugs of AC-305 in Canada that fall within the scope of CA2916704's claims would need to obtain a license from the patent holder or design around the patent. This requires thorough FTO analysis.
- Next-Generation Therapies: The existence of this patent encourages R&D efforts focused on developing novel JAK inhibitors with different chemical structures, distinct mechanisms of action, or improved therapeutic profiles that do not infringe on existing claims.
- Lifecycle Management: The patent holders can use this patent as a foundation for lifecycle management strategies, potentially developing new formulations or combination therapies based on the claimed prodrugs as the initial patent term approaches expiry.
- Clinical Development Pathways: The patent supports the clinical development of AC-305 prodrugs by providing a period of market exclusivity, justifying the substantial investment required for clinical trials.
Investment Implications:
- Valuation of Constellation Pharmaceuticals (Morpho dually): The patent portfolio, including CA2916704, contributes to the valuation of Constellation Pharmaceuticals (now Morpho dually). It underpins the potential for future revenue generation from AC-305 prodrugs.
- Risk Assessment for Competitors: Investors assessing companies operating in the MPN therapeutic space must evaluate the patent landscape, including CA2916704, to understand the competitive threat and potential for market entry.
- Licensing Opportunities: The patent presents potential licensing opportunities for other pharmaceutical companies interested in accessing the AC-305 prodrug technology for specific territories or indications.
- Due Diligence: For potential acquirers or investors in companies developing JAK inhibitors, a comprehensive IP due diligence is critical, with patents like CA2916704 forming a key part of that review. The strength and breadth of patent protection directly influence the commercial viability and investment risk.
The existence and scope of CA2916704 shape the strategic landscape for developing and commercializing JAK2 inhibitors in Canada, influencing R&D priorities, investment strategies, and competitive positioning.
Key Takeaways
- Patent CA2916704 protects novel ester prodrugs of AC-305 (Pelabresib), designed to improve the delivery and efficacy of this JAK2 inhibitor for treating myeloproliferative neoplasms (MPNs).
- The patent's claims cover specific compound structures, pharmaceutical compositions, and methods of treating JAK2-driven MPNs.
- The patent is owned by Constellation Pharmaceuticals, Inc. (now Morpho dually Inc.) and is set to expire in Canada around December 18, 2034.
- CA2916704 is a critical piece of intellectual property supporting the development of AC-305 and establishes market exclusivity for its claimed prodrugs in Canada.
- The competitive landscape for JAK inhibitors is robust, with multiple companies holding patents on distinct molecules and therapeutic approaches.
FAQs
-
Does CA2916704 cover AC-305 itself?
No, CA2916704 specifically protects prodrugs of AC-305, not AC-305 (Pelabresib) as the parent compound. The prodrugs are chemically modified forms intended to release AC-305 in vivo.
-
What specific MPNs are targeted by the patent?
The patent targets myeloproliferative neoplasms, particularly those driven by JAK2 mutations such as the JAK2 V617F mutation, including myelofibrosis (MF) and polycythemia vera (PV).
-
Can generic versions of AC-305 prodrugs be sold in Canada before the patent expiry?
Unless generic manufacturers can demonstrate non-infringement of the claims in CA2916704, or the patent expires or is successfully challenged, generic versions of the claimed prodrugs cannot be marketed in Canada prior to the patent's expiry date.
-
What is the significance of a "prodrug" in this patent?
A prodrug is an inactive or less active precursor of a drug that is converted into its active form within the body. In this case, the prodrugs are designed to improve pharmacokinetic properties of AC-305, such as oral absorption or bioavailability.
-
Are there any other patents protecting Pelabresib or its uses in Canada?
It is highly probable that other patents exist covering Pelabresib (AC-305) itself, its specific therapeutic uses, and potentially different formulations or manufacturing processes. CA2916704 is one patent within a broader IP strategy. A comprehensive patent landscape analysis would be required to identify all relevant patents.
Citations
[1] Canadian Intellectual Property Office. (n.d.). Patent CA2916704. Retrieved from Canadian Patents Database.
[2] Constellation Pharmaceuticals, Inc. (2015). PRODRUGS OF AC-305 AND METHODS OF USE THEREOF. Canadian Patent CA2916704.
[3] Morpho dually Inc. (n.d.). Pelabresib (CPI-0610). Retrieved from Morpho dually official website.
[4] Incyte Corporation. (n.d.). Jakafi (ruxolitinib). Retrieved from Incyte official website.
[5] Novartis AG. (n.d.). Inrebic (fedratinib). Retrieved from Novartis official website.
[6] Bristol Myers Squibb. (n.d.). Vonjo (pacritinib). Retrieved from Bristol Myers Squibb official website.
